Payment overview · 2025
General Payments
$154.94
10 reported records · 7 companies
Healthcare provider profile · identity verified
Margaret V. Cox, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT SMITH, AR · NPI 1407010952
Verified facts
What the public records show
CMS Open Payments records show Margaret V. Cox, MD received $154.94 in general payments during 2025 across 10 reported records.
GlaxoSmithKline, LLC. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.72 | 26.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.26 | 20.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.91 | 12.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.81 | 10.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.44 | 10.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.69 | 9.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.11 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.94 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.17 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 27 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 891 | 262 |
| Levothyroxine Sodium | Levothyroxine Sodium | 605 | 163 |
| Omeprazole | Omeprazole | 568 | 169 |
| Losartan Potassium | Losartan Potassium | 534 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 161 |
| Lisinopril | Lisinopril | 492 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 116 |
| Gabapentin | Gabapentin | 394 | 112 |
| Jardiance | Empagliflozin | 290 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 257 | 68 |
| Metformin Hcl Er | Metformin Hcl | 240 | 80 |
| Alendronate Sodium | Alendronate Sodium | 233 | 74 |
| Tramadol Hcl | Tramadol Hcl | 225 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 69 |
| Montelukast Sodium | Montelukast Sodium | 222 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 64 |
| Trazodone Hcl | Trazodone Hcl | 196 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 62 |
| Potassium Chloride | Potassium Chloride | 190 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 53 |
| Meloxicam | Meloxicam | 178 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 51 |
| Metformin Hcl | Metformin Hcl | 171 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 51 |
| Ozempic | Semaglutide | 168 | 39 |
| Allopurinol | Allopurinol | 165 | 44 |
| Eliquis | Apixaban | 165 | 31 |
| Furosemide | Furosemide | 160 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 148 | 35 |
| Carvedilol | Carvedilol | 147 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 138 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 27 |
| Pregabalin | Pregabalin | 125 | 25 |
| Simvastatin | Simvastatin | 125 | 33 |
| Bupropion Xl | Bupropion Hcl | 124 | 39 |
| Glipizide Er | Glipizide | 124 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 122 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 30 |
| Sertraline Hcl | Sertraline Hcl | 107 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 27 |
| Famotidine | Famotidine | 105 | 28 |
| Celecoxib | Celecoxib | 103 | 30 |
| Mounjaro | Tirzepatide | 100 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 26 |
| Mirtazapine | Mirtazapine | 87 | 23 |
| Finasteride | Finasteride | 86 | 21 |
| Estradiol | Estradiol | 84 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 22 |
| Spironolactone | Spironolactone | 78 | 22 |
| Temazepam | Temazepam | 76 | 16 |
| Ezetimibe | Ezetimibe | 73 | 24 |
| Alprazolam | Alprazolam | 72 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 12 |
| Clonazepam | Clonazepam | 69 | 16 |
| Azelastine Hcl | Azelastine Hcl | 68 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 18 |
| Memantine Hcl | Memantine Hcl | 63 | 19 |
| Eszopiclone | Eszopiclone | 62 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 44 |
| Myrbetriq | Mirabegron | 59 | 14 |
| Ondansetron Odt | Ondansetron | 58 | 30 |
| Buspirone Hcl | Buspirone Hcl | 57 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 54 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 21 |
| Synthroid | Levothyroxine Sodium | 53 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 18 |
| Donepezil Hcl | Donepezil Hcl | 47 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 14 |
| Atenolol | Atenolol | 44 | 11 |
| Linzess | Linaclotide | 42 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 40 | 24 |
| Chlorthalidone | Chlorthalidone | 39 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Prednisone | Prednisone | 38 | 23 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 37 | 12 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Valacyclovir | Valacyclovir Hcl | 37 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 12 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 11 |
| Topiramate | Topiramate | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Nystatin | Nystatin | 31 | 17 |
| Valsartan | Valsartan | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 15 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 15 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Trulance | Plecanatide | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | 11 |
| Telmisartan | Telmisartan | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Estarylla | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.94 · 10 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, LEQVIO, NURTEC ODT, SHINGRIX, TRELEGY ELLIPTA, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error